南京医药(600713) - 2014 Q3 - 季度财报
NPCNPC(SH:600713)2014-10-30 16:00

Financial Performance - Operating revenue for the first nine months reached CNY 16,443,589,131.81, a growth of 14.44% year-on-year[8] - Net profit attributable to shareholders increased by 110.43% to CNY 51,023,158.62 for the first nine months[8] - The weighted average return on equity rose to 4.982%, an increase of 2.660 percentage points compared to the previous year[8] - Total operating revenue for Q3 2014 reached ¥5,706,659,664.73, an increase of 16.4% compared to ¥4,900,749,971.85 in Q3 2013[36] - Net profit attributable to the parent company for Q3 2014 was ¥25,229,551.01, significantly higher than ¥5,310,038.73 in Q3 2013, marking an increase of 376.5%[37] - The total profit for the first nine months was a loss of ¥12,639,466.44, contrasting with a profit of ¥31,242,390.92 in the same period last year, marking a decrease of approximately 140.4%[42] Cash Flow - Cash flow from operating activities turned positive with a net amount of CNY 48,200,215.10, compared to a negative cash flow in the same period last year[8] - Cash flow from operating activities for the first nine months was ¥48,200,215.10, a recovery from a negative cash flow of ¥545,547,455.42 in the previous year[46] - The cash outflow from operating activities was ¥14,546,480,256.25, compared to ¥12,148,944,927.34 in the previous year, indicating an increase of approximately 19.7%[46] - The company's cash and cash equivalents at the end of the period were ¥729,470,091.10, down from ¥1,124,362,779.92 at the end of the previous year, a decrease of approximately 35.1%[47] - Net cash flow from operating activities improved to $119.33 million, compared to a negative cash flow of $660.46 million in the same period last year[51] - The net cash flow from financing activities was negative at $404.12 million, contrasting with a positive cash flow of $560.77 million in the same period last year[52] Assets and Liabilities - Total assets increased by 14.07% to CNY 11,258,727,304.19 compared to the end of the previous year[8] - Accounts receivable increased by 34.64% to CNY 5,901,180,916.87 compared to the beginning of the year[12] - The company reported a significant increase in accounts payable, which rose by 30.53% to CNY 4,015,266,298.94[12] - The company's total liabilities as of September 30, 2014, were 9,965,389,001.06 RMB, compared to 8,531,049,310.76 RMB at the beginning of the year, reflecting an increase of about 16.8%[28] - The company's current assets totaled 9,861,293,473.92 RMB, up from 8,454,576,438.03 RMB at the start of the year, indicating a growth of approximately 16.6%[26] - The long-term equity investment balance as of September 30, 2014, was 62,055,721.42 RMB, down from 117,889,623.88 RMB at the beginning of the year, indicating a decrease of approximately 47.4%[26] Shareholder Information - The number of shareholders reached 52,316 by the end of the reporting period[10] - The company's equity attributable to shareholders decreased to 1,034,151,124.19 RMB from 1,052,812,139.98 RMB, a decline of about 1.8%[28] - The total equity attributable to shareholders increased to ¥913,638,658.60 from ¥835,695,127.62 at the beginning of the year, an increase of 9.3%[32] Financial Expenses - Financial expenses rose by 31.64% to ¥252,207,007.60, primarily due to increased financing needs from business expansion[14] - The company incurred financial expenses of ¥24,714,660.93 in the third quarter, significantly higher than ¥8,751,489.24 in the same period last year, representing an increase of about 182.5%[40] Investment Activities - Cash received from the disposal of subsidiaries increased by 2171.78% to ¥23,432,923.59, reflecting successful divestitures[15] - The company’s long-term equity investments decreased due to the disposal of stakes in certain subsidiaries[13] - Cash inflow from investment activities totaled $185.46 million, down from $215.42 million year-over-year[52] Regulatory and Compliance - The report indicates that the financial statements have not been audited, ensuring transparency in the financial reporting process[6] - The company committed to avoiding any direct or indirect competition with its own business operations, ensuring compliance with competitive regulations[19] - The company received approval from the China Securities Regulatory Commission for a non-public issuance of A-shares, indicating future capital raising efforts[18]